Hamdard Labs To Conduct Clinical Trials Of Immunity Booster Medicines Against COVID-19
- byDoctor News Daily Team
- 07 July, 2025
- 0 Comments
- 0 Mins
New Delhi: Health and wellness firm Hamdard Laboratories on Tuesday said it is planning to conduct clinical trial of its immunity booster medicines to assess their effectiveness against COVID-19. The company has submitted the proposal for required permission from the concerned authorities and the clinical trial will be conducted at Hamdard Institute of Medical Sciences and Research, New Delhi, Hamdard Laboratories said in a statement.
The Ministry of AYUSH has invited inputs from Ayush practitioners and institutions including colleges, universities, hospitals, research institutes, manufacturers, association's etc to prevent infection from COVID-19, it added.
The company has submitted its inputs to the AYUSH department, Hamdard Laboratories said.
The ministry's task force is examining the proposals submitted by Ayush institutions. They will then be send to Indian Council of Medical Research (ICMR), which will register such clinical proposals and evaluate the outcome of studies for clinical efficacy of such products, it added.
"Currently, preventive measures are the only way to fight the coronavirus and having a strong immunity system is one of the ways to minimize the impact of the virus on the body," Hamdard Laboratories (Medicine Division) Chairman Abdul Majeed said.
Hamdard Laboratories foresees that clinical trials of immunity boosting Unani medicines will further scientifically establish clinical evidence, he added.
"Our products are developed with natural formulae that combine the benefits of time tested herbs for strengthening of innate immunity which may be helpful in minimizing the impact of COVID-19 virus through development of specific antibodies," Majeed said.
The company is hopeful that the trials will yield positive results and will help in fighting the COVID-19 pandemic, he added.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Pathologist's signature on medical reports not mus...
- 02 November, 2025
UP Eyes Japanese Investment: 125 Pharma Giants Inv...
- 02 November, 2025
Delhi Govt to recruit 1,593 senior resident doctor...
- 02 November, 2025
Former Drug Inspector's Office Clerk Jailed for Ta...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!